The Clinical Presentations of Nitrous Oxide Users in an Emergency Department

Jhe-Ping Lin 1,2, Shi-Ying Gao 1,2 and Chih-Chuan Lin 1,2, *

1 Lin-Kou Medical Center, Department of Emergency Medicine, Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan; stanley27616159@hotmail.com (J.-P. L.); s78092359@cgmh.org.tw (S.-Y. G.)
2 College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan
* Correspondence: bearuncle@yahoo.com

Abstract: Today, the concomitant abuse of nitrous oxide (N\textsubscript{2}O) and illicit drugs is evident and problematic. However, there are few reports regarding the clinical manifestations of N\textsubscript{2}O users when they present to the emergency department (ED). The purpose of this study was to describe the clinical presentations, the associated illicit substances used in combination, and the outcomes in N\textsubscript{2}O users visiting the ED. This was a retrospective observational cohort study. All N\textsubscript{2}O adult users admitted to the ED at Linkou Chang Gung Memorial Hospital between 2012 and 2020 were included. Demographic variables, clinical symptoms, and examination results were collected from medical records. Univariate comparisons were conducted between pure N\textsubscript{2}O users and combined illicit drug users. A total of 40 patients were included, 24 of which were pure N\textsubscript{2}O users. Limb weakness and numbness accounted for the majority of chief complaints. Neurologic symptoms were the most common clinical manifestations (90%). A more severe ED triage level, faster heart rate, greater agitation, and cardiovascular symptoms were significantly noted in combined illicit drug users. In ED, limb numbness/weakness should arouse physicians’ awareness of patients using N\textsubscript{2}O. Combined use of N\textsubscript{2}O and illicit drugs can cause great harm to health.

Keywords: nitrous oxide; emergency department; fast toxidrome; limb numbness

1. Introduction

Today, the abuse of nitrous oxide (N\textsubscript{2}O) is evident. The lifetime prevalence of N\textsubscript{2}O abuse has been reported to range between 2% and 15.8% among adolescents and young adults [1,2]. The Global Drug Survey (GDS) in 2014 confirmed N\textsubscript{2}O as a very common drug used in the UK and US (38.6% and 29.4% lifetime prevalence) [3]. The abuse of N\textsubscript{2}O remains problematic. For example, there has been a sharp increase in the number of patients with neurological disorders associated with recreational use of nitrous oxide (N\textsubscript{2}O) in China [4]. Unfortunately, there is no epidemiological data of national prevalence of N\textsubscript{2}O abuse in Taiwan. However, due to increasing cases of death after N\textsubscript{2}O abuse found by autopsy, the Taiwan government had added N\textsubscript{2}O to the controlled substance list and forbidden its recreational use by law since 30 October 2020.

Although the use of N\textsubscript{2}O is not associated with significant harm, the adverse effects of N\textsubscript{2}O abuse are well known to include neurologic sequelae such as myeloneuropathy and subacute combined degeneration, as well as psychiatric effects such as psychosis and mood changes [5,6]. Other medical effects such as pneumomediastinum [7], venous thrombosis [8], pulmonary embolism [9], and even death have been reported [10,11]. However, there are few reports regarding the clinical manifestations of N\textsubscript{2}O users when they present to the emergency department (ED). In the ED, physicians do not always know the kinds of substances used by patients due to self-reporting. The concomitant use of N\textsubscript{2}O with other illicit drugs has been reported in the literature [12–15]. Accordingly, diagnosis may be quite complicated when N\textsubscript{2}O users present to the ED. Therefore, describing the
clinical picture of N$_2$O users and determining concomitant use of other illicit drugs may help ED physicians to provide better care to patients. Thus, the purpose of this study was to describe the clinical presentations, the associated illicit substances used in combination, and the outcomes in N$_2$O users seeking medical help in the ED.

2. Materials and Methods

2.1. Study Design and Patient Selection

We designed a retrospective observational cohort study. All N$_2$O adult users admitted to the ED at Linkou Chang Gung Memorial Hospital (LCGMH) during the study period (2012–2020) were included. LCGMH is an academic teaching hospital located in north Taiwan, with 3700 beds and approximately 14,000 monthly ED visits. The hospital ethics committee (202102441B0, approval date is 27 December 2021) granted approval for this study.

2.2. Data Collection

We designed a standardized abstraction form to retrospectively collect all variables from electronic medical records. The following variables were collected: patient’s demographics including age and gender, vital signs at ED triage, ED triage level, patient’s reason for ED visit, positive physical examination of any neurological, psychiatric, cardiovascular, respiratory, or other symptom upon ED admission, patient’s disposition, poison severity score, and outcomes. ED triage level is based on the Taiwan Triage and Acuity Scale (TTAS), a five-level scale used for disease urgency assessment in the study, which is a modification of the Canadian Triage and Acuity Scale (CTAS). There are five levels of urgency: Level 1, resuscitation; Level 2, emergency; Level 3, urgent; Level 4, less urgent; and Level 5, non-urgent [16]. Laboratory variables, including complete blood cell count, as well as serum glucose, sodium, potassium, creatinine, blood urea nitrogen, alanine aminotransferase, and vitamin B12 level (if any) on ED admission, were also recorded. Patients’ urine samples (if any) were sent to be analyzed by the lab to screen (EIA method) for opioids, methamphetamine, MDMA, ketamine, and cannabinoids. The results of the drug screen were also collected.

Examinations such as magnetic resonance imaging, nerve conduction velocity tests, and evoked potentials were arranged after medical ward admission. The results of these examinations were also abstracted.

2.3. Statistical Methods

Since the data distribution did not meet the normality assumption, data are expressed as percentages or medians (25th–75th percentiles) unless otherwise indicated. The Mann–Whitney U-test for numerical variables and the chi-squared test for categorical variables were used in univariate comparisons between both study groups: pure N$_2$O users and concomitant illicit drug users.

3. Results

3.1. Demographic Characteristics of ED Patients Intentionally Using N$_2$O

A total of 40 patients were included in the study, 24 (12 males) of which were pure N$_2$O users with a median age of 25.5 (21.5–29) years. A total of 16 patients (10 males) were concomitant illicit drug users, with a median age of 25 (22–28) years. A total of 11 patients had self-reported N$_2$O exposure amount. The average usage frequency of N$_2$O was 4.9 ± 2.7 times per week. The average dose of use was 14.9 ± 8.7 bullets per week (one bullet of N$_2$O approximately equivalent to 30–40 balloons). The mean duration of N$_2$O exposure was 25.1 ± 30.5 months. The demographic characteristics of the patients are listed in Table 1. Many of reasons for the ED visit and various chief complaints were reported by patients. However, limb weakness and limb numbness were the most common, accounting for ~50% of the cohort.
Table 1. Demographic characteristics of ED patients intentionally using N\textsubscript{2}O.

| Characteristics | Presenting symptoms | Pure N\textsubscript{2}O Users n = 24 | Concomitant Illicit Drug Users n = 16 | p-Value |
|-----------------|---------------------|--------------------------------------|--------------------------------------|---------|
| Gender (M)      |                     | 12 (50)                              | 10 (62.5)                            | 0.65    |
| Age             |                     | 25.5 (21.5–29)                       | 25 (22–28)                           | 0.86    |
| ED triage       | 1                   | 0 (0)                                | 2 (12.5)                             |         |
|                 | 2                   | 4 (16.67)                            | 8 (50)                               | <0.01   |
|                 | 3                   | 20 (83.33)                           | 6 (37.5)                             |         |
| Vital signs     | Respiration rate (/min) | 18 (18–19.5)                       | 19 (17–20)                           | 0.74    |
|                 | Heart rate (/min)    | 92.5 (85.5–105)                      | 111 (97.5–127)                       | 0.01    |
|                 | SBP/DBP (mmHg)       | 130 (114.5–139)                      | 130 (112–140)                        | 0.91    |
|                 | Body temperature (°C)| 36.9 (36.5–37.1)                     | 37.05 (36.7–37.45)                   | 0.37    |
|                 | SpO\textsubscript{2} | 97 (96–99)                           | 97 (96–98)                           | 0.39    |
|                 | GCS (median)         | 15 (15–15)                           | 15 (13–15)                           | 0.11    |
| Reasons for being in ED | Abdomen pain | 2 (8.33)                             | 0 (0)                                |         |
|                 | Agitation           | 3 (12.5)                             | 3 (18.75)                            |         |
|                 | Amnesia             | 1 (4.17)                             | 0 (0)                                |         |
|                 | Chest pain          | 1 (4.17)                             | 0 (0)                                |         |
|                 | Conscious change    | 2 (8.33)                             | 4 (25)                               |         |
|                 | Dyspnea             | 1 (4.17)                             | 0 (0)                                |         |
|                 | GTC                 | 1 (4.17)                             | 0 (0)                                |         |
|                 | Headache            | 1 (4.17)                             | 0 (0)                                |         |
|                 | Hemoptysis          | 0 (0)                                | 1 (6.25)                             |         |
|                 | Limb numbness       | 5 (20.83)                            | 1 (6.25)                             |         |
|                 | Limb weakness       | 7 (29.17)                            | 7 (43.75)                            |         |
| Symptoms/signs  | Neurologic symptoms | Conscious change                     | 7 (29.17)                            | 6 (37.5) | 0.84    |
|                 |                     | 12 (50)                              | 3 (18.75)                            |         |
|                 |                     | Seizure                              | 1 (4.17)                             | 3 (18.75) | 0.98    |
|                 |                     | Headache                             | 1 (4.17)                             | 0 (0)   | 0.6     |
|                 |                     | Amnesia                              | 4 (16.67)                            | 0 (0)   | 0.12    |
|                 |                     | Paresthesia/limb numbness            | 17 (70.83)                           | 9 (56.25)| 0.54    |
|                 |                     | Limb weakness                        | 11 (45.83)                           | 8 (50)  | 1       |
|                 | Psychiatric symptoms| Agitation                           | 4 (16.67)                            | 10 (62.5)| 0.01    |
|                 |                     | Hallucination                        | 6 (25)                               | 4 (25)  | 1       |
|                 |                     | Dependence                           | 2 (8.33)                             | 5 (31.25)| 0.99    |
|                 | Hematology          | Pancyctopenia                        | 1 (4.16)                             | 1 (6.25) |         |
|                 |                     | Normal                               | 23 (95.84)                           | 15 (93.75)| 0.05    |
|                 | Cardiovascular system | Shock                              | 0 (0)                                | 2 (12.5) |         |
|                 |                     | Palpitation                          | 1 (4.16)                             | 3 (18.75)|         |
|                 |                     | Normal                               | 23 (95.84)                           | 11 (68.75)| 0.42    |
|                 | GI/GU organ systems | AKI                                  | 0 (0)                                | 2 (12.5) |         |
|                 |                     | Abdominal pain                       | 2 (8.33)                             | 1 (6.25) |         |
|                 |                     | Constipation                         | 2 (8.33)                             | 0 (0)   |         |
|                 |                     | Urine retention                      | 0 (0)                                | 1 (6.25) |         |
|                 |                     | Normal                               | 20 (83.34)                           | 12 (75)  |         |
Table 1. Cont.

| Characteristics Presenting symptoms | Pure N\(_2\)O Users \(n = 24\) | Concomitant Illicit Drug Users \(n = 16\) | \(p\)-Value |
|-------------------------------------|---------------------------------|---------------------------------|-------------|
| Dyspnea                             | 1 (4.16)                        | 0 (0)                           |             |
| Hemoptysis                          | 0 (0)                           | 1 (6.25)                        |             |
| Respiratory muscle weakness         | 1 (4.16)                        | 0 (0)                           |             |
| Normal                              | 22 (91.68)                      | 15 (93.75)                      | 0.15        |
| Poison severity score (PSS)         |                                 |                                 |             |
| 1                                   | 9 (37.5)                        | 3 (18.75)                       |             |
| 2                                   | 14 (58.33)                      | 11 (68.75)                      |             |
| 3                                   | 1 (4.17)                        | 2 (12.5)                        |             |
| Disposition                         |                                 |                                 | 0.59        |
| ED observation                      | 11 (45.83)                      | 6 (37.5)                        |             |
| Admission to ward                   | 12 (50)                         | 8 (50)                          |             |
| ICU admission                       | 1 (4.17)                        | 2 (12.5)                        |             |
| Admission length (days)             | 9 (6–13)                        | 5.5 (3–12)                      | 0.26        |

Limb weakness was reported by 29.17%, while limb numbness was reported by 20.83% of pure N\(_2\)O users. On the other hand, the corresponding values were 43.7% and 6.25%, respectively, in concomitant illicit drug users. Neurologic symptoms were the most common clinical manifestations (36 of 40 patients, 90%). Paresthesia and limb numbness (65%), limb weakness (47.5%), and unsteady gait (37.5%) were commonly reported.

3.2. Comparison between Pure N\(_2\)O Users and Concomitant Illicit Drug Users

Concomitant illicit drug users presented with a more severe ED triage level (\(p < 0.01\)) and faster heart rate (92.5 vs. 111 beats/min, \(p = 0.01\)), as well as more agitation (16.67% vs. 62.5%, \(p < 0.01\)), and cardiovascular symptoms such as palpitation (4.16% vs. 18.75%, \(p = 0.05\)) than pure N\(_2\)O users. In contrast, there was no statistically significant difference in other neurologic or respiratory symptoms, as well as in poison severity score (PSS) and patient outcome, between both groups.

On the other hand, half of the patients were either left in the ED for further clinical observation or admitted to the medical ward. A total of 17 patients were left in the ED for observation. Among these cases, seven patients complained of limbs weakness, six patients presented with agitated moods, two patients mentioned abdomen pain, one patient had chest pain, and one patient suffered from headache. These patients had received symptomatic treatment and then were discharged when they became better after ED observation. There were no cases of patient mortality in the study cohort.

Laboratory investigation results are shown in Table 2. Concomitant illicit drug users had a higher white blood cell count and Hb level, while there was no statistically significant difference in serum vitamin B12 level between both groups (270.4, IQR: 152–1772 vs. 491.3, IQR: 200.4–860, \(p = 0.74\)). Among the 10 patients with elevated white blood cell count, two patients had infections at the same time, and two patients had acute kidney injury and rhabdomyolysis at the same time.

However, eight of 21 (38%) patients initially had a low serum vitamin B12 level (<211 pg/mL). Of the 14 patients checked for serum homocysteine, 12 (85.7%) were found to have a level exceeding the upper limit of 12.42 mmol/L. However, there was no statistically significant difference in serum homocysteine level between both groups. Concomitantly used substances included ketamine (\(n = 11\)), MDMA (\(n = 5\)), cathinone (\(n = 4\)), methamphetamine (\(n = 2\)), and cannabinoids (\(n = 1\)).
Table 2. Laboratory investigations of ED patients intentionally using N₂O.

| Lab Variables      | Pure N₂O Users n = 24 | Concomitant Illicit Drug Users n = 16 | p-Value |
|--------------------|------------------------|---------------------------------------|---------|
| White cell count   | 7 (5.7–8.2)            | 10.6 (8.4–14.85)                      | 0.01    |
| Hemoglobin         | 13.1 (11.4–14)         | 14.3 (12.65–15.2)                     | 0.04    |
| MCV                | 89.8 (86.3–94.6)       | 91.55 (86.05–96.4)                    | 0.93    |
| RDW                | 14.4 (13.8–16.8)       | 14 (13.45–15.1)                       | 0.25    |
| Platelet           | 269 (252–373)          | 282 (201–351.5)                       | 0.53    |
| Blood glucose      | 109 (100–119)          | 108 (104–137)                         | 0.76    |
| Na                 | 140 (138–142)          | 138.5 (136.5–140)                     | 0.21    |
| K                  | 3.7 (3.5–3.8)          | 3.45 (3.25–4.1)                       | 0.76    |
| BUN                | 24.4 (23.45–25.5)      | 22.5 (19.5–24.1)                      | 0.36    |
| Cr                 | 0.77 (0.62–0.94)       | 0.86 (0.73–1.01)                      | 0.13    |
| ALT                | 33 (16–51)             | 31 (19–87)                            | 0.82    |
| Vitamin B12 *      | 270.4 (152–1772)       | 491.3 (200.4–860)                     | 0.74    |
| Homocysteine *     | 33.1 (11.4–57.9)       | 58 (29.55–98.6)                       | 0.32    |

*Vitamin B12, n = 21; homocysteine, n = 14.

3.3. Findings of Magnetic Resonance Imaging, Nerve Conduction Velocity Tests, and Evoked Potentials

In the study, eight patients were subjected to MRI examination of the cervical spine; three were found normal, four showed symmetrically hyperintense lesions in posterior columns with edema of the posterior spinal cord, and one showed hyperintense lesions in the posterior and posterolateral spinal cord. A total of 17 patients underwent nerve conduction velocity (NCV) tests; 2 were normal, and the other 15 exhibited sensory motor polyneuropathy and demyelinating polyneuropathy. Five patients had their evoked potentials (EP) examined; two were normal, whereas the other three had a peripheral sensory conduction defect with sensory polyneuropathy.

3.4. The Severe Poisoned Patients

There were one pure N₂O user and two concomitant illicit drug users admitted to the ICU. We observed one severe case (a 19-year-old male with a history of pure N₂O inhalation for 3 years) with severe motor nerve denervation, lower-limb muscle weakness (MRC grade 0–2), and respiratory muscle weakness, as well as subsequent aspiration pneumonia, then acute respiratory failure. The patient was managed with emergent intubation in the ED and admitted to the ICU. Upon recovering from the pneumonia, he was transferred to the rehabilitation ward for neurological sequelae, with a total of 87 days of admission. There were two concomitant illicit drug users admitted to the ICU. The first case was a 21-year-old male who had concomitant abuse of N₂O, LSD, and cathinone for one day. The patient presented with visual and auditory hallucination then sudden collapse, lying on the ground for an unknown period. When the patient was brought to the ED, he was comatose with hyperthermia, tachyarrhythmia, and hypertension; the initial survey revealed rhabdomyolysis, acute kidney injury, and demanding myocardial ischemia. He ended up with emergency intubation and ICU admission. Another case was a 27-year-old male who abused N₂O and cathinone in an unknown amount. The patient then had a sudden consciousness change with generalized tonic convolution. Due to poor consciousness in the ED, he was intubated for airway protection and admitted to the ICU as well.

4. Discussion

4.1. N₂O Intoxication

N₂O can lead to acute intoxication and chronic neurologic or psychiatric sequelae. N₂O is more water-soluble than oxygen. Once inhaled, it can rapidly diffuse and enter the bloodstream, resulting in dilution of the oxygen volume and decreased oxygen delivery.
Upon acute intoxication, it may induce seizures, arrhythmia, respiratory irritation, or even respiratory or cardiac arrest. Inhaling N₂O in a closed space can lead to asphyxia [17]. Interstitial emphysema and pneumomediastinum secondary to barotrauma after N₂O inhalation have also been reported [7,18]. Consistent with a previous study, we observed acute consciousness changes, seizures, or respiratory arrest episodes in some patients after substantial N₂O inhalation in a short period with or without concomitant illicit drug use.

We found that 50% of N₂O users presented to the ED with limb weakness or numbness, regardless of whether they were pure N₂O users or concomitant illicit drug users. Therefore, this parameter is important for ED physicians to identify N₂O use. N₂O interferes with the vitamin B₁₂ metabolic pathway, leading to reduced recycling of homocysteine to methionine. Methionine is required for nerve myelination. Long-term N₂O abuse can lead to vitamin B₁₂ deficiency, thus causing demyelination within the central and peripheral nervous systems [19]. Additionally, mental symptoms, anemia, skin changes, and immune disorders are related to chronic N₂O exposure [20]. Consequently, chronic N₂O intoxication can lead to severe neurological sequelae such as myeloneuropathy, subacute combined degeneration, peripheral neuropathy, and myelopathy [20]. The most common clinical symptoms included paresthesia, unsteady gait, and weakness, as also reported in [21].

4.2. Combined Use of N₂O and Illicit Drugs

To the best of our knowledge, this was the first study to describe and compare the ED clinical presentations of pure N₂O users and concomitant illicit drug users. There has been evidence of steadily increasing N₂O recreational use [4,22]. Almost half of the users in this study indicated the combined use of other drugs. The most common substances used in combination in the study cohort were CNS stimulants, such as ketamine, MDMA, and cathinones. Five of the 16 (31.2%) concomitant illicit drug users were polydrug use (more than three kinds). Toxic coffee packets are a popular form of synthetic cathinones consumed in Taiwan [23]. Due to the polydrug effect, these patients had diverse clinical presentations.

N₂O inhalation causes an increase in the level of the serum homocysteine. Elevated homocysteine level is an independent risk factor for cardiovascular events [24]. Previous studies have shown that increased homocysteine levels are associated with endothelial dysfunction and increased rates of thrombosis and atherosclerosis [25]. Recreational N₂O abuse leads to ischemic stroke, myocardial infarction, and venous thrombosis in adolescents which are previously reported [26–29]. Concerning concomitant illicit drug use, amphetamine and its derivatives are stimulants which have profound effects on the cardiovascular and cerebrovascular systems leading to tachycardia, arrhythmia, vasoconstriction, and hypertension [30]. Amphetamine may cause congestive heart failure, accelerate atherosclerosis, and is associated with myocardial infarction and aortic dissection [31]. Novel psychoactive substances (NPS), such as synthetic cathinones and synthetic cannabinoids, are popular illicit drugs, which also cause severe hazard to health. They pose excessive CNS and cardiovascular effects to abusers, ranging from seizures, paranoid, hallucination, to myocardial infarction, and cardiac arrest [32–34]. Accordingly, N₂O concomitant drug abuse will cause tremendous hazard to the cardiovascular system and cause more toxic effects.

Although the study found no statistically significant differences in poison severity score, disposition, or admission length between both patient groups, a more severe triage level, faster initial heart rate, greater agitation, and more cardiovascular symptoms were significant in concomitant illicit drug users. We believe that, under the effect of multiple stimulants, a “fast toxidrome” was more evident in these patients. Due to apparently abnormal vital signs and a more severe triage level, we assume that ED physicians paid more attention to these patients with immediate and proper treatment. This may explain the lack of a significant difference in outcomes between both patient groups. For example, the higher white blood cell count and Hb level recorded in concomitant illicit drug users may have led ED physicians to administer more intravenous fluid to stabilize the patients.
4.3. Examinations of N₂O Intoxication

Laboratory tests for N₂O intoxication are not specific. Due to its short half-life and rapid clearance, it is difficult to detect N₂O in screening tests. A decreased level of vitamin B₁₂ and increased levels of methylmalonic acid and homocysteine can be found in patients with chronic N₂O intoxication. Due to the poor correlation between serum and tissue levels, functional vitamin B₁₂ deficiency can occur in the presence of a normal serum vitamin B₁₂ level [35]. Some N₂O users have reportedly self-treated these deficiencies with cyanocobalamin, which can also affect the lab test results [36]. Accordingly, a raised serum level of methylmalonic acid and homocysteine is more sensitive for diagnosis but may not be readily available [5]. In our study, eight of 21 (38%) patients initially had a low serum vitamin B₁₂ level. The prevalence of vitamin B₁₂ deficiency among N₂O abusers was similar to other studies [37]. A total of 12 of 14 (85.7%) patients presented an elevated homocysteine level. Interestingly, only 4 out of 12 patients who had an elevated homocysteine level showed a low serum vitamin B₁₂ level, highlighting homocysteine as a more sensitive diagnostic tool. In addition to the lab test, diagnosis can be supported by atypical MRI findings or abnormal nerve conduction studies [12]. Characteristically, MRI demonstrates symmetrical T₂ hyperintensity within the posterior columns, with variable involvement of the lateral corticospinal tracts [38,39].

4.4. Limitations

Our study had some limitations. One of the major limitations was the low patient number. Therefore, interpreting the results, such as prevalence, was not suitable. Therefore, the finding of high prevalence of concomitant abuse in our study may be biased as well, even though our patient number was relatively bigger than or similar to the previous studies [4,6,37,39,40]. Studies of higher evidence should be carried out for a better interpretation of this issue. This study was retrospective and was based on a chart review. Therefore, the study design had inherent limitations such as recall bias, in addition to incomplete chart records or patients concealing their history of N₂O exposure. The N₂O inhalation amount and frequency were not recorded in most cases; hence, their relationship with the evaluated parameters was not possible. There is no formal protocol or guideline for N₂O intoxication management in our hospital. Instead, examination surveys and management are currently based on the ED physicians’ clinical judgement. There is no confirmatory chemical analysis in case of urinary positive screening of drugs of abuse, which may cause false positive results. The pattern of concomitant illicit drug use may differ across countries or regions; therefore, this study’s findings (such as faster heart rate, palpitation, and agitation) of a fast toxidrome should be interpreted cautiously. Due to the limitations mentioned above, we will consider prosecuting a prospective observational study in the future.

5. Conclusions

The recreational use of N₂O is increasing steadily, especially in adolescents and young adults. Almost half of N₂O abusers are concomitant illicit drug users in the study, and this has become an obvious public health issue. In the ED, limb numbness/weakness should arouse physicians’ awareness of patients using N₂O. For patients with fast toxidromes, ED physicians should also be aware of the combined use of stimulants.

N₂O intoxication can lead to severe neurological sequelae, and combined illicit drug use can cause great harm to health. ED physicians should pay additional attention to these patients with immediate and proper treatment.

Author Contributions: Conceptualization, C.-C.L.; methodology, C.-C.L.; software, S.-Y.G.; validation, C.-C.L., J.-P.L. and S.-Y.G.; formal analysis, S.-Y.G.; investigation, J.-P.L.; resources, C.-C.L. and J.-P.L.; data curation, J.-P.L. and S.-Y.G.; writing—original draft preparation, J.-P.L. and C.-C.L.; writing—review and editing, C.-C.L.; supervision, C.-C.L.; project administration, C.-C.L. and J.-P.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.
Institutional Review Board Statement: The study was approved by the Institutional Review Board of Chang Gung Medical Foundation (IRB No. 20210244180), approval date is 27 December 2021.

Informed Consent Statement: Informed consent was waived since this was a retrospective study with no impact on patients’ medical management.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Garland, E.L.; Howard, M.O.; Perron, B.E. Nitrous oxide inhalation among adolescents: Prevalence, correlates, and co-occurrence with volatile solvent inhalation. *J. Psychoact. Drugs* **2009**, *41*, 337–347. [CrossRef] [PubMed]
2. Wu, L.-T.; Pilowsky, D.J.; Schlenger, W.E. Inhalant Abuse and Dependence Among Adolescents in the United States. *J. Am. Acad. Child Adolesc. Psychiatry* **2004**, *43*, 1206–1214. [CrossRef]
3. Kaar, S.J.; Ferris, J.; Waldron, J.; Devaney, M.; Ramsey, J.; Winstock, A.R. Up: the rise of nitrous oxide abuse. An international survey of contemporary nitrous oxide use. *J. Psychopharmacol.* **2016**, *30*, 395–401. [CrossRef] [PubMed]
4. Zheng, D.; Ba, F.; Bi, G.; Guo, Y.; Gao, Y.; Li, W. The sharp rise of neurological disorders associated with recreational nitrous oxide use in China: A single-center experience and a brief review of Chinese literature. *J. Neurol.* **2020**, *267*, 422–429. [CrossRef] [PubMed]
5. Garakani, A.; Jaffe, R.J.; Savla, D.; Welch, A.K.; Protin, C.A.; Bryson, E.O.; McDowell, D.M. Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: a systematic review of the case literature. *Am. J. Addict.* **2016**, *25*, 358–369. [CrossRef]
6. Wang, S.; Wu, G.; Wang, T.; Yu, A.; Wang, Y.; Liu, S. Physical and Psychological Characteristics of Nitrous Oxide Abusers during the COVID-19 Pandemic: An Observational Study. *Psychosomatics*. [PubMed]
7. LiPuma, J.P.; Wellman, J.; Stern, H.P. Nitrous oxide abuse: A new cause of pneumomediastinum. *Radiology* **1982**, *145*, 602. [CrossRef]
8. Pratt, D.N.; Patterson, K.C.; Quin, K. Venous thrombosis after nitrous oxide abuse, a case report. *J. Thromb. Thrombolysis* **2020**, *49*, 501–503. [CrossRef]
9. Molina, M.F.; Al Saud, A.A.; Al Mulhim, A.A.; Liteplo, A.S.; Shokoohi, H. Nitrous oxide inhalant abuse and massive pulmonary embolism in COVID-19. *Am. J. Emerg. Med.* **2020**, *38*, 1549.e1–1549.e2. [CrossRef]
10. Garriott, J.; Petty, C.S. Death from inhalant abuse: Toxicological and pathological evaluation of 34 cases. *Clin. Toxicol.* **1980**, *16*, 305–315. [CrossRef]
11. Bowen, S.E.; Daniel, J.; Balster, R.L. Deaths associated with inhalant abuse in Virginia from 1987 to 1996. *Drug Alcohol Depend.* **1999**, *53*, 239–245. [CrossRef]
12. Pugliese, R.S.; Slagle, E.J.; Oettinger, G.R.; Neuburger, K.J.; Ambrose, T.M. Subacute combined degeneration of the spinal cord in a patient abusing nitrous oxide and self-medicating with cyanocobalamin. *Am. J. Health-Syst. Pharm.* **2015**, *72*, 952–957. [CrossRef] [PubMed]
13. Cousaert, C.; Heylens, G.; Audenaert, K. Laughing gas abuse is no joke. An overview of the implications for psychiatric practice. *Clin. Neurol. Neurosurg.* **2013**, *115*, 859–862. [CrossRef] [PubMed]
14. Garakani, A.; Welch, A.K.; Jaffe, R.J.; Protin, C.A.; McDowell, D.M. Psychosis and low cyanocobalamin in a patient abusing nitrous oxide and cannabis. *Psychosomatics* **2014**, *55*, 715–719. [CrossRef] [PubMed]
15. DiMaio, V.J.; Garriott, J.C. Four deaths resulting from abuse of nitrous oxide. *J. Forensic Sci.* **1978**, *23*, 169–172. [CrossRef] [PubMed]
16. Ng, C.-J.; Hsu, K.-H.; Kuan, J.-T.; Chiu, T.-F.; Chen, W.-K.; Lin, H.-J.; Bullard, M.J.; Chen, J.-C. Comparison between Canadian triage and acuity scale and Taiwan triage system in emergency departments. *J. Formos. Med. Assoc.* **2010**, *109*, 828–837. [CrossRef]
17. Wagner, S.A.; Clark, M.A.; Wesche, D.L.; Doedens, D.J.; Lloyd, A.W. Asphyxial deaths from the recreational use of nitrous oxide. *J. Forensic Sci.* **1992**, *37*, 1088–1015. [CrossRef] [PubMed]
18. Amiri, F.; Neghab, M.; Shouroki, F.K.; Yousefinejad, S.; Hassanzadeh, J. Early, Subclinical Hematological Changes Associated with Occupational Exposure to High Levels of Nitrous Oxide. *Toxics* **2018**, *6*, 70. [CrossRef]
19. Thompson, A.G.; Leite, M.I.; Lunn, M.P.; Bennett, D.L. Whippits, nitrous oxide and the dangers of legal highs. *Pract. Neurol.* **2015**, *15*, 207–209. [CrossRef]
20. Xiang, Y.; Li, L.; Ma, X.; Li, S.; Xue, Y.; Yan, P.; Chen, M.; Wu, J. Recreational Nitrous Oxide Abuse: Prevalence, Neurotoxicity, and Treatment. *Neurotox. Res.* **2021**, *39*, 975–985. [CrossRef]
21. Oussalah, A.; Julien, M.; Levy, J.; Hajjar, O.; Franczak, C.; Stephan, C.; Laugel, E.; Wandzel, M.; Filhine-Tresarrieu, P.; Green, R.; et al. Global Burden Related to Nitrous Oxide Exposure in Medical and Recreational Settings: A Systematic Review and Individual Patient Data Meta-Analysis. *J. Clin. Med.* **2019**, *8*, 551. [CrossRef]
22. Bethmont, A.; Harper, C.E.; Chan, B.S.; Dawson, A.H.; McAnulty, J. Increasing illicit use of nitrous oxide in presentations to NSW emergency departments. *Med. J. Aust.* **2019**, *211*, 429. [CrossRef]
23. Chou, H.H.; Hsieh, C.H.; Chaou, C.H.; Chen, C.K.; Yen, T.H.; Liao, S.C.; Seak, C.J.; Chen, H.Y. Synthetic cathinone poisoning from ingestion of drug-laced “instant coffee packets” in Taiwan. *Hum. Exp. Toxicol.* 2021, 40, 1403–1412. [CrossRef]

24. Graham, I.M.; Daly, L.E.; Refsum, H.M.; Robinson, K.; Brattström, L.E.; Ueland, P.M.; Palma-Reis, R.J.; Boers, G.H.; Sheahan, R.G.; Israelsson, B.J. Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project. *JAMA* 1997, 277, 1775–1781. [CrossRef]

25. Chambers, J.C.; McGregor, A.J.T.L. Acute hyperhomocysteinaemia and endothelial dysfunction. *Lancet* 1998, 351, 36–37. [CrossRef]

26. Bajaj, D.; Agrawal, A.; Gupta, S.; Bajaj, S.J.C. Recreational nitrous oxide abuse causing ischemic stroke in a young patient: A rare case report. *Cureus* 2018, 10, e3761. [CrossRef] [PubMed]

27. Oomens, T.; Riezebos, R.K.; Amoroso, G.; Kuipers, R.S. Case report of an acute myocardial infarction after high-dose recreational nitrous oxide use: A consequence of hyperhomocysteinaemia? *Eur. Heart J.-Case Rep.* 2021, 5, ytaa557. [CrossRef] [PubMed]

28. Bajaj, D.; Agrawal, A.; Gupta, S.; Bajaj, S.J.C. Recreational nitrous oxide abuse causing ischemic stroke in a young patient: A rare case report. *Cureus* 2018, 10, e3761. [CrossRef] [PubMed]

29. Sun, W.; Liao, J.-P.; Hu, Y.; Ma, J.; Wang, G.-F. Pulmonary embolism and deep vein thrombosis caused by nitrous oxide abuse: A case report. *World J. Clin. Cases* 2019, 7, 4057–4062. [CrossRef] [PubMed]

30. Al-Imam, A. Adverse effects of amphetamines on the cardiovascular system: Review and retrospective analyses of trends. *Glob. J. Health Sci.* 2017, 9, 102. [CrossRef]

31. White, S.R. Amphetamine toxicity. In *Seminars in Respiratory and Critical Care Medicine*; Thieme Medical Publishers, Inc.: New York, NY, USA, 2002; pp. 027–036.

32. Kelly, J.P. Cathinone derivatives: A review of their chemistry, pharmacology and toxicology. *Drug Test. Anal.* 2011, 3, 439–453. [CrossRef]

33. Weinstein, A.M.; Rosca, P.; Fattore, L.; London, E.D. Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. *Front. Psychiatry* 2017, 8, 156. [CrossRef] [PubMed]

34. Cannizzaro, C.; Maia, G.; Argo, A.; Brancato, A.; Roda, G.; Casagni, E.; Fumagalli, L.; Valoti, E.; Fraldi, R.; Procaccianti, P.; et al. Behavioural and pharmacological characterization of a novel cannabinomimetic adamantane-derived indole, APICA, and considerations on the possible misuse as a psychotropic spice abuse, in C57Bl/6J mice. *Forensic Sci. Int.* 2016, 265, 6–12. [CrossRef]

35. Sanders, R.D.; Weimann, J.; Maze, M. Biologic effects of nitrous oxide: A mechanistic and toxicologic review. *Anesthesiology* 2008, 109, 707–722. [CrossRef]

36. Cheng, H.M.; Park, J.H.; Hernstadt, D. Subacute combined degeneration of the spinal cord following recreational nitrous oxide use. *BMJ Case Rep.* 2013, 2013, bcr2012008509. [CrossRef]

37. Dang, X.T.; Nguyen, T.X.; Nguyen, T.T.H.; Ha, H.T. Nitrous Oxide-Induced Neuropathy among Recreational Users in Vietnam. *Int. J. Environ. Res. Public Health* 2021, 18, 6230. [CrossRef]

38. Ravina, B.; Loewner, L.A.; Bank, W. MR findings in subacute combined degeneration of the spinal cord: A case of reversible cervical myelopathy. *AJR. Am. J. Roentgenol.* 2000, 174, 863–865. [CrossRef]

39. Chiew Angela, L.; Raubenheimer Jacques, E.; Ingrid, B.; Buckley Nicholas, A.; Therese, B.; Betty, C.; Jonathan, B. Just “nanging” around—harmful nitrous oxide use. A retrospective case series and review of internet searches, social media posts and the coroner’s database. *Intern. Med. J.* 2021. [CrossRef] [PubMed]

40. Keddie, S.; Adams, A.; Kelso, A.R.; Turner, B.; Schmierer, K.; Gnanapavan, S.; Malaspina, A.; Giovannoni, G.; Basset, I.; Noyce, A.J. No laughing matter: Subacute degeneration of the spinal cord due to nitrous oxide inhalation. *J. Neurol.* 2018, 265, 1089–1095.